From comparative analysis of previous sequencing data on more than 900 prostate cancer patients, emerged evidence for the identification of 22 new putative genes harboring coding mutations, such as truncating mutations of the TBL1XR1 and ZMYM3 genes that could act as prostate cancer tumor suppressors; furthermore, this study evidenced non-coding NEAT1 and FOXA1 mutations, acting as driver mutational events [65]. This evidence concerns the gene FOXA1 and prostate cancer.